Patients
supraventricular or ventricular arrhythmia, arrhythmia, malignancy, cardiovascular or cerebrovascular disease, hypersensitivity, autoimmune disease, Cancer
ADVERSE EVENT, ADVANCED SOLID TUMOR, ARRHYTHMIA, ATRIAL FIBRILLATION, SOLID TUMORS, ONCOLOGY, HEART FAILURE, HYPERSENSITIVITY, AUTOIMMUNE DISEASE, CANCER
The study enrolled patients aged 18–70 years with a histologically or cytologically confirmed advanced or metastatic solid tumors that failed standard treatment or had no standard therapies available. Additional key eligibility criteria included at least one measurable lesion as assessed by the Response Evaluation Criteria in Advanced Solid Tumors (RECIST) version 1.1; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; a life expectancy of at least 12 weeks (3 months); and adequate hematologic, renal, and liver functions. Patients were excluded if they had an active autoimmune disease requiring systemic treatment; prior use of corticosteroids (>10 mg/daily of prednisone or equivalent) or immunosuppressive medication within 14 days before the start of study treatment; had clinically significant cardiovascular or cerebrovascular disease within 3 months; had grade ≥2 [National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0] arrhythmia or heart failure, atrial fibrillation, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention; had received radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular targeted therapy within 4 weeks prior to first dose of study treatment; known hypersensitivity to any mAb, QL1604 and/or any of its excipients; had received a live antitumor vaccine; and a known additional malignancy within 5 years before study start.